Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Theseus Pharmaceuticals, Inc. operates in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This action is being processed by 1 distinct examiner, SHOWALTER, ALEXANDER KEITH, in 1 distinct art unit. The 1 pending office action represents the current focus of the company's Biotechnology & Pharmaceuticals intellectual property efforts.
The busiest examiner for this portfolio is SHOWALTER, ALEXANDER KEITH, who is managing 1 pending office action. Since there is only 1 distinct examiner, SHOWALTER, ALEXANDER KEITH is the sole individual responsible for the current pending workload. This concentration in 1 distinct art unit simplifies the tracking of prosecution developments for the company.
Practitioners should note that the 1 distinct examiner handles the entire pending inventory, allowing for a direct interaction with the patent office. The presence of 1 distinct art unit indicates that the company's current filings are concentrated in a specific technical area. This 1 pending office action serves as the primary indicator of the company's progress in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHOWALTER, ALEXANDER KEITH | 1 | 54.4% | +26.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18506625 | MACROCYCLIC COMPOUNDS AND USES THEREOF | SHOWALTER, ALEXANDER KEITH | 12d |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18506625 | MACROCYCLIC COMPOUNDS AND USES THEREOF | SHOWALTER, ALEXANDER KEITH | 1629 | §112 | Non-Final OA | 12d | Pending | Nov 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial